IL141232A0 - Use of camptothecin derivatives, with reduced gastrointestinal toxicity - Google Patents

Use of camptothecin derivatives, with reduced gastrointestinal toxicity

Info

Publication number
IL141232A0
IL141232A0 IL14123299A IL14123299A IL141232A0 IL 141232 A0 IL141232 A0 IL 141232A0 IL 14123299 A IL14123299 A IL 14123299A IL 14123299 A IL14123299 A IL 14123299A IL 141232 A0 IL141232 A0 IL 141232A0
Authority
IL
Israel
Prior art keywords
camptothecin derivatives
gastrointestinal toxicity
reduced gastrointestinal
sodium chloride
reduced
Prior art date
Application number
IL14123299A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9810043A external-priority patent/FR2782009B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL141232A0 publication Critical patent/IL141232A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
IL14123299A 1998-08-05 1999-08-03 Use of camptothecin derivatives, with reduced gastrointestinal toxicity IL141232A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9810043A FR2782009B1 (fr) 1998-08-05 1998-08-05 Utilisation de derives de la comptothecine, avec une toxicite gastro-intestinale reduite
US9631898P 1998-08-12 1998-08-12
PCT/FR1999/001916 WO2000007605A1 (fr) 1998-08-05 1999-08-03 Utilisation de derives de la camptothecine, avec une toxicite gastro-intestinale reduite

Publications (1)

Publication Number Publication Date
IL141232A0 true IL141232A0 (en) 2002-03-10

Family

ID=26234482

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14123299A IL141232A0 (en) 1998-08-05 1999-08-03 Use of camptothecin derivatives, with reduced gastrointestinal toxicity

Country Status (24)

Country Link
US (1) US6476043B1 (cs)
EP (1) EP1102594B1 (cs)
JP (1) JP2002522392A (cs)
KR (1) KR20010072228A (cs)
AT (1) ATE217531T1 (cs)
AU (1) AU771195B2 (cs)
BG (1) BG64641B1 (cs)
CA (1) CA2340020A1 (cs)
CZ (1) CZ295775B6 (cs)
DE (1) DE69901506T2 (cs)
DK (1) DK1102594T3 (cs)
EA (1) EA002917B1 (cs)
EE (1) EE04264B1 (cs)
ES (1) ES2176009T3 (cs)
GE (1) GEP20043254B (cs)
HU (1) HUP0103314A3 (cs)
ID (1) ID27253A (cs)
IL (1) IL141232A0 (cs)
NO (1) NO20010454D0 (cs)
NZ (1) NZ509859A (cs)
PT (1) PT1102594E (cs)
SK (1) SK1732001A3 (cs)
TR (1) TR200100331T2 (cs)
WO (1) WO2000007605A1 (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1749540B1 (en) 1999-05-17 2010-10-13 Cancer Research Ventures Limited Compositions for improving bioavailability of orally administered drugs
CA2295429A1 (en) * 2000-01-06 2001-07-06 Michael Michael Treatment or prevention of diarrhea
DE602005024923D1 (de) 2004-02-13 2011-01-05 Yakult Honsha Kk Wässrige lösung mit einem camptothecin
US20050197355A1 (en) * 2004-03-02 2005-09-08 Henegar Kevin E. Compounds useful in preparing camptothecin derivatives
CN1946421B (zh) 2004-04-27 2013-07-17 威尔斯达特生物制剂公司 使用病毒和喜树碱进行的癌症治疗
JP2006151950A (ja) * 2004-11-05 2006-06-15 Oto Corporation:Kk 納豆菌培養エキス含有製剤及び納豆菌培養エキスの保存方法
DE602006009901D1 (de) * 2005-02-07 2009-12-03 Fermion Oy Verfahren zur herstellung von 7-ethyl-10-hydroxycamptothecin
JP5133703B2 (ja) * 2005-02-08 2013-01-30 フェルミオン オサケ ユキチュア ［１，４’］ビピペリジニル−１’−カルボニルクロリドまたはその塩酸塩の製造方法
CA2591074C (en) * 2005-02-08 2015-01-20 Fermion Oy Preparation method
CA2503099A1 (en) * 2005-04-18 2006-10-18 Kabushiki Kaisha Yakult Honsha Pharmaceutical compositions containing camptothecins
RU2435586C2 (ru) 2005-07-14 2011-12-10 Веллстат Байолоджикс Корпорейшн Лечение рака с применением вирусов, фторпиримидинов и камптотецинов

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284579A (en) * 1979-07-17 1981-08-18 The United States Of America As Represented By The Of The Department Of Health & Human Services (N-Phosphonacetyl-L-aspartato)(1,2-diaminocyclchexane)platinum(II) or alkali metal salt
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS58154582A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
CH663353A5 (de) * 1984-03-28 1987-12-15 Joaquin Amat Larraz Mittel gegen krebs.
CA1332413C (en) * 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US5225404A (en) * 1989-11-06 1993-07-06 New York University Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
IT1247937B (it) * 1991-05-16 1995-01-05 Ist Naz Ric Sul Cancro Associazione farmaceutica ad attivita' antineoplastica
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
WO1996011005A2 (en) * 1994-10-06 1996-04-18 Atlas Leon T Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases

Also Published As

Publication number Publication date
JP2002522392A (ja) 2002-07-23
EE200100066A (et) 2002-06-17
CZ2001382A3 (en) 2001-05-16
DE69901506T2 (de) 2002-11-28
AU771195B2 (en) 2004-03-18
BG64641B1 (bg) 2005-10-31
AU5168799A (en) 2000-02-28
EA002917B1 (ru) 2002-10-31
ATE217531T1 (de) 2002-06-15
EE04264B1 (et) 2004-04-15
ES2176009T3 (es) 2002-11-16
DE69901506D1 (de) 2002-06-20
TR200100331T2 (tr) 2001-07-23
US6476043B1 (en) 2002-11-05
CA2340020A1 (fr) 2000-02-17
SK1732001A3 (en) 2001-06-11
ID27253A (id) 2001-03-22
WO2000007605A1 (fr) 2000-02-17
KR20010072228A (ko) 2001-07-31
EP1102594B1 (fr) 2002-05-15
DK1102594T3 (da) 2002-08-26
GEP20043254B (en) 2004-06-25
NO20010454L (no) 2001-01-26
CZ295775B6 (cs) 2005-11-16
PT1102594E (pt) 2002-10-31
HUP0103314A3 (en) 2002-07-29
BG105216A (en) 2001-10-31
NZ509859A (en) 2003-09-26
EA200100214A1 (ru) 2001-08-27
NO20010454D0 (no) 2001-01-26
HUP0103314A2 (hu) 2002-01-28
EP1102594A1 (fr) 2001-05-30

Similar Documents

Publication Publication Date Title
BR9508554A (pt) Preparação farmaceuticamente estável de oxaliplatina
MY121517A (en) Anticonvulsant derivatives useful in reducing blood glucose levels
TR200102603T2 (tr) Antitümör aktiviteye sahip olan kamptotesin türevleri
BG103969A (en) C-4"-substituted macrolide derivatives
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
BG103947A (en) Derivatives of 9-oxymerythromycin
AP2004003120A0 (en) Combined use of antitumor indolopyrrolocarbazole derivatives and other antitumor agent
EP1017675A4 (en) HIGHLY LIPOPHILIC CAMPTOTHECIN DERIVATIVES
IL141232A0 (en) Use of camptothecin derivatives, with reduced gastrointestinal toxicity
ZA200108004B (en) Echinocandin/carbohydrate complexes.
IL154755A0 (en) Antitumor theraphy comprising distamycin derivatives
IL127851A0 (en) Inhibition of TNF activity
HUP9802736A2 (hu) 1,4-Dihidropiridin-származékok alkalmazása artériafal ateroszklerózisos degradálódásának megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
EE200200660A (et) Akrüloüüldistamütsiini derivaati sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritudravimpreparaat
YU5301A (sh) Primena derivata kamptotecina sa smanjenom gastro-intestinalnom toksičnošću
SI1102594T1 (en) Use of sodium chloride to reduce the gastrointestinal toxicity of camptothecin derivatives
UA36163A (uk) Спосіб профілактики олігоануричної форми гострої ниркової недостатності
TR200102262T2 (tr) Koroner müdahale ile ilgili kardiovasküler olayların önlenmesi veya azaltılması için yöntem.
UA36162A (uk) Спосіб моделювання поліуричної форми гострої ниркової недостатності